BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
3/7/2018 9:03:26 AM | Browse: 956 | Download: 1205
 |
Received |
|
2018-01-08 18:33 |
|
Peer-Review Started |
|
2018-01-08 22:02 |
|
To Make the First Decision |
|
2018-02-05 03:34 |
|
Return for Revision |
|
2018-02-09 07:43 |
|
Revised |
|
2018-02-15 21:53 |
|
Second Decision |
|
2018-03-07 00:45 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2018-03-07 00:51 |
|
Articles in Press |
|
2018-03-07 00:51 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2018-03-07 06:04 |
|
Publish the Manuscript Online |
|
2018-03-07 09:03 |
| ISSN |
1948-9358 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Endocrinology & Metabolism |
| Manuscript Type |
Retrospective Study |
| Article Title |
Blood glucose changes surrounding initiation of tumor-necrosis factor inhibitors and conventional disease-modifying anti-rheumatic drugs in veterans with rheumatoid arthritis
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Patrick R Wood, Evan Manning, Joshua F Baker, Bryant England, Lisa Davis, Grant W Cannon, Ted R Mikuls and Liron Caplan |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| U.S. Veterans Affairs |
IIR 14-048-3 |
|
| Corresponding Author |
Liron Caplan, MD, PhD, Associate Professor, Denver Veterans Affairs Medical Center, Division of Rheumatology, University of Colorado, POB 6511,B115, Aurora, CO 80045, United States. liron.caplan@ucdenver.edu |
| Key Words |
Disease modifying anti-rheumatic drugs; Drug toxicity; Glucocorticoids; Rheumatoid arthritis; Tumor necrosis factor inhibitors |
| Core Tip |
Clinicians should be cognizant of the potential for rare hypoglycemic effects of the conventional disease-modifying anti-rheumatic drugs hydroxychloroquine and sulfasalazine, in addition to the well-known hyperglycemic effects of glucocorticoids. Although case reports describe dramatic sporadic hypoglycemic events with the initiation of tumor necrosis factor inhibitors, these effects were not confirmed in our large retrospective study. |
| Publish Date |
2018-03-07 09:03 |
| Citation |
Wood PR, Manning E, Baker JF, England B, Davis L, Cannon GW, Mikuls TR, Caplan L. Blood glucose changes surrounding initiation of tumor-necrosis factor inhibitors and conventional disease-modifying anti-rheumatic drugs in veterans with rheumatoid arthritis. World J Diabetes 2018; 9(2): 53-58 |
| URL |
http://www.wjgnet.com/1948-9358/full/v9/i2/53.htm |
| DOI |
http://dx.doi.org/10.4239/wjd.v9.i2.53 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
